ProStrakan Group plc, the international specialty pharmaceutical company, today announces that it has received approval from the US Food and Drug Administration (FDA) for Sancuso®, ProStrakan’s novel, patent protected transdermal patch for the prevention of chemotherapy-induced nausea and vomiting (CINV).
The details can be read here.
No comments:
Post a Comment